拉丁美洲淋巴增生性研究小组(GELL)对SARS CoV-2 / COVID - 19大流行状态下淋巴瘤管理的共识

IF 0.2 Q4 ONCOLOGY Revista Colombiana de Cancerologia Pub Date : 2020-05-22 DOI:10.35509/01239015.690

Juan Alejandro Ospina Idárraga, Humberto Martínez-Cordero, Henry Idrobo Quintero, Conrad Ortiz Alfaro, Lina María Martínez Correa, J. García, Luis Malpica, J. Castillo, M. A. Torres, L. Villela, Myrna G Candelaria, Alana Von Glasenapp, B. Beltrán, Sally Paredes, D. E. Castro, Virginia Prates, Marcos Di Stefano, E. Riva, Virginia Abello Polo, Juan Choque, Camila Peña, Christine Rojas, Fabiola Valvert Gamboa, Lorena Fiad

{"title":"拉丁美洲淋巴增生性研究小组(GELL)对SARS CoV-2 / COVID - 19大流行状态下淋巴瘤管理的共识","authors":"Juan Alejandro Ospina Idárraga, Humberto Martínez-Cordero, Henry Idrobo Quintero, Conrad Ortiz Alfaro, Lina María Martínez Correa, J. García, Luis Malpica, J. Castillo, M. A. Torres, L. Villela, Myrna G Candelaria, Alana Von Glasenapp, B. Beltrán, Sally Paredes, D. E. Castro, Virginia Prates, Marcos Di Stefano, E. Riva, Virginia Abello Polo, Juan Choque, Camila Peña, Christine Rojas, Fabiola Valvert Gamboa, Lorena Fiad","doi":"10.35509/01239015.690","DOIUrl":null,"url":null,"abstract":"In December 2019, the cause of COVID-19 disease, SARS-CoV2 virus was detected for the first time in China. The virus spread quickly through Europe and Asia, and a couple months after arrived Latin America. Elderly patients and those with chronic disease, including cancer, have high risk of mortatily because of COVID-19. Consequently, many doubts arise in the group of health professionals in charge of cancer treatment during the pandemic because they must handle risk-benefit of providing treatment to patients who are at the base with an increased risk for manifestations derived from COVID-19. In this consensus we propose recommendations for hematology professionals who provide treatment to patients with any type of lymphoma, looking to clarify the clinical picture during the pandemic","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2020-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19\",\"authors\":\"Juan Alejandro Ospina Idárraga, Humberto Martínez-Cordero, Henry Idrobo Quintero, Conrad Ortiz Alfaro, Lina María Martínez Correa, J. García, Luis Malpica, J. Castillo, M. A. Torres, L. Villela, Myrna G Candelaria, Alana Von Glasenapp, B. Beltrán, Sally Paredes, D. E. Castro, Virginia Prates, Marcos Di Stefano, E. Riva, Virginia Abello Polo, Juan Choque, Camila Peña, Christine Rojas, Fabiola Valvert Gamboa, Lorena Fiad\",\"doi\":\"10.35509/01239015.690\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In December 2019, the cause of COVID-19 disease, SARS-CoV2 virus was detected for the first time in China. The virus spread quickly through Europe and Asia, and a couple months after arrived Latin America. Elderly patients and those with chronic disease, including cancer, have high risk of mortatily because of COVID-19. Consequently, many doubts arise in the group of health professionals in charge of cancer treatment during the pandemic because they must handle risk-benefit of providing treatment to patients who are at the base with an increased risk for manifestations derived from COVID-19. In this consensus we propose recommendations for hematology professionals who provide treatment to patients with any type of lymphoma, looking to clarify the clinical picture during the pandemic\",\"PeriodicalId\":42496,\"journal\":{\"name\":\"Revista Colombiana de Cancerologia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2020-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Colombiana de Cancerologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35509/01239015.690\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Cancerologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35509/01239015.690","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 5

摘要

2019年12月，中国首次发现新冠肺炎病原SARS-CoV2病毒。该病毒在欧洲和亚洲迅速传播，几个月后到达拉丁美洲。老年患者和患有慢性疾病(包括癌症)的患者因COVID-19死亡的风险很高。因此，在大流行期间负责癌症治疗的卫生专业人员群体中出现了许多疑虑，因为他们必须处理为基地患者提供治疗的风险-收益，这些患者的风险增加了COVID-19引发的症状。在这一共识中，我们为为任何类型淋巴瘤患者提供治疗的血液学专业人员提出建议，希望在大流行期间澄清临床情况

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19

In December 2019, the cause of COVID-19 disease, SARS-CoV2 virus was detected for the first time in China. The virus spread quickly through Europe and Asia, and a couple months after arrived Latin America. Elderly patients and those with chronic disease, including cancer, have high risk of mortatily because of COVID-19. Consequently, many doubts arise in the group of health professionals in charge of cancer treatment during the pandemic because they must handle risk-benefit of providing treatment to patients who are at the base with an increased risk for manifestations derived from COVID-19. In this consensus we propose recommendations for hematology professionals who provide treatment to patients with any type of lymphoma, looking to clarify the clinical picture during the pandemic

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista Colombiana de Cancerologia ONCOLOGY-

自引率

50.00%

发文量

期刊介绍： The Revista Colombiana de Cancerología is an official publication of the Instituto Nacional de Colombia (INC). The Revista is published quarterly with the aim of broadening and disseminating knowledge in the field of oncology. The Revista publishes articles on: molecular carcinogenic mechanisms and treatment responses; cancer epidemiology; clinical features and treatment of neoplastic disease and public health campaigns to control cancer. Manuscripts which contain original material shall be accepted for possible publication. Neither the article nor any part of its contents (including statistical or graphic content) may have been published or submitted for publication in any media other than the Revista Colombiana de Cancerología. No acceptance shall be made of preliminary reports (abstracts or posters) presented at scientific meetings, neither of press releases on programmed meetings. All manuscript copies shall be placed at the disposition of the Journal Editorial Board. Under exceptional circumstances, secondary publications in Spanish or other languages may be submitted, provided they comply with certain conditions which justify said submission.